Browsing Tag
petosemtamab
3 posts
Genmab’s $8bn takeover of Merus: What it means for biotech M&A and the race to control antibody innovation
Find out how Genmab’s $8B acquisition of Merus and its petosemtamab asset is reshaping the oncology biotech race and investor sentiment today.
Why Merus is the hottest takeover target in oncology right now—Genmab said to be frontrunner
Genmab is reportedly close to acquiring Merus in a high-stakes biotech deal that could reshape the oncology sector. Read the full breakdown now.
Merus N.V. stock soars on breakthrough cancer trial: What drove MRUS to the top gainers list?
Merus N.V. stock jumped 32% on breakthrough cancer trial data. Find out what’s driving MRUS and what could come next for this biotech leader.